Celltrion Eyes Price Advantage For ‘Latecomer’ Bevacizumab

Planning To Leverage Biosimilar Cost Competitiveness After Filings In Korea And US

 
• By David Wallace
  
Vial injection syringe dollars
Celltrion is planning to leverage its cost competitiveness on bevacizumab • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products